Access cutting-edge pancreatic cancer treatment through this clinical trial at a research site in Tucson. Study-provided care at no cost to qualified participants.
Access pancreatic cancer specialists in Tucson at no cost
This study follows strict safety protocols and ethical guidelines
All study-related pancreatic cancer treatment provided free
The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) deletion.
Sponsor: Bristol-Myers Squibb
Check if you qualify for this pancreatic cancer clinical trial in Tucson, AZ
If you're searching for pancreatic cancer treatment options in Tucson, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Tucson research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pancreatic cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.